BioMarin Pharmaceutical Inc. ($BMRN) Stock Forecast: Up 5.1% Today

What is BioMarin Pharmaceutical Inc.?

BioMarin Pharmaceutical Inc. (BMRN) is a biopharmaceutical company specializing in therapies for rare genetic and metabolic diseases. The company has a strong product pipeline and is considered an attractive stock with significant upside potential.

Why is BioMarin Pharmaceutical Inc. going up?

BMRN stock is up 5.1% on Feb 19, 2026 17:21

• BioMarin's bullish movement today can be attributed to the positive sentiment surrounding the company, as highlighted by analysts and institutional investors increasing their stakes in the company.
• The upcoming conference call to discuss the fourth quarter and full-year 2025 financial results likely generated optimism among investors about the company's performance and future prospects.
• The continued interest from institutional investors, such as Aberdeen Group plc reducing its stake and New York Life Investment Management LLC making a new investment, indicates confidence in BioMarin's long-term growth potential.
• LSV Asset Management's significant increase in stake further reinforces the positive outlook on BioMarin, contributing to the bullish momentum in the stock price.

BMRN Price Chart

BMRN Technical Analysis

BMRN News

BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET

BioMarin Pharmaceutical Inc. announced it will host a conference call and webcast on Monday, February 23, 2026, at 4:30 p.m. ET. The call will discuss the company's fourth quarter and full-year 2025 financial results and provide a business update. Alexander Hardy, President and CEO, will host the event, which will be accessible via dial-in numbers and a live audio webcast on BioMarin's investor website.

https://www.marketscreener.com/news/biomarin-to-host-fourth-quarter-and-full-year-2025-financial-results-conference-call-and-webcast-on-ce7e5dd9d98cf123

What Makes BioMarin (BMRN) so Attractive

BioMarin Pharmaceutical (BMRN) is highlighted as an attractive biotechnology stock with significant upside potential, based on analyst sentiment and price targets. Piper Sandler reiterated an Overweight rating despite a reduced price target, still implying over 40% upside. The company specializes in therapies for rare genetic diseases and has a strong product pipeline.

https://finviz.com/news/311934/what-makes-biomarin-bmrn-so-attractive

Aberdeen Group plc Sells 80,297 Shares of BioMarin Pharmaceutical Inc. $BMRN

Aberdeen Group plc reduced its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 8.2% in the third quarter, selling 80,297 shares and retaining 902,751 shares valued at $48.89 million. Other institutional investors like NewEdge Advisors LLC and Empowered Funds LLC increased their holdings in BioMarin during recent quarters. The article also provides BioMarin Pharmaceutical's current stock performance, market capitalization, P/E ratio, and recent analyst price targets and ratings.

https://www.marketbeat.com/instant-alerts/filing-aberdeen-group-plc-sells-80297-shares-of-biomarin-pharmaceutical-inc-bmrn-2026-02-16/

New York Life Investment Management LLC Makes New Investment in BioMarin Pharmaceutical Inc. $BMRN

New York Life Investment Management LLC has initiated a new investment in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by acquiring 19,783 shares valued at approximately $1.07 million in the third quarter. Several other institutional investors also adjusted their positions in BioMarin, which maintains a "Moderate Buy" consensus rating from analysts with an average target price of $88.29. The biopharmaceutical company specializes in therapies for rare genetic and metabolic diseases, with 98.71% institutional ownership of its stock.

https://www.marketbeat.com/instant-alerts/filing-new-york-life-investment-management-llc-makes-new-investment-in-biomarin-pharmaceutical-inc-bmrn-2026-02-14/

LSV Asset Management Purchases 812,284 Shares of BioMarin Pharmaceutical Inc. $BMRN

LSV Asset Management significantly increased its stake in BioMarin Pharmaceutical Inc. in the third quarter, purchasing an additional 812,284 shares to own a total of 845,500 shares valued at approximately $45.79 million. Hedge funds and other institutional investors own a substantial 98.71% of BioMarin's stock. Wall Street analysts currently rate BioMarin as a "Moderate Buy" with a consensus target price of $88.29, significantly higher than its recent trading price around $59.87.

https://www.marketbeat.com/instant-alerts/filing-lsv-asset-management-purchases-812284-shares-of-biomarin-pharmaceutical-inc-bmrn-2026-02-14/

Trending Today

Teladoc Health Inc. ($TDOC) Stock Forecast: Up 5.6% Today

Tilray Inc. ($TLRY) Stock Forecast: Up 5.8% Today

Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Up 6.3% Today

SolarEdge Technologies, Inc. ($SEDG) Stock Forecast: Up 7.9% Today

DENTSPLY SIRONA Inc. ($XRAY) Stock Forecast: Down 6.4% Today

FuelCell Energy ($FCEL) Stock Forecast: Up 5.9% Today

Shoals Technologies Group Inc. ($SHLS) Stock Forecast: Down 5.4% Today

Wingstop Inc. ($WING) Stock Forecast: Down 6.8% Today

Delta Air Lines Inc. ($DAL) Stock Forecast: Down 5.1% Today

United Continental Holdings Inc. ($UAL) Stock Forecast: Down 5.3% Today

BioMarin Pharmaceutical Inc. Price History

13.00.2026 - BMRN Stock was down 5.1%

• The announcement of BioMarin Pharmaceutical's estimated 2025 revenue of $3.2 billion and the strong performance of Voxzogo at $920 million at the recent conference should have been positive news. However, the market may have reacted negatively due to concerns about the company's ability to meet these revenue targets.
• The hiring of Arpit Davé as Chief Digital and Information Officer to accelerate rare disease therapies shows the company's commitment to innovation. However, the market might have interpreted this move as a signal of potential challenges in the current R&D and commercial operations that require urgent attention.
• Despite the outlined growth strategy, pipeline progress, and Amicus integration positioning BioMarin for sustained double-digit compound annual growth rate, investors may have focused on the weak long-term outlook highlighted in the tactical trading analysis. This could have contributed to the bearish movement in the stock.
• The absence of clear long-term support signals and elevated downside risk might have spooked investors, leading to a sell-off of the stock despite the positive developments and revenue projections.

19.11.2025 - BMRN Stock was up 7.7%

• The appointment of Rashmi Ramchandani as the new chief accounting officer brings fresh leadership to BioMarin, potentially signaling positive changes within the company.
• Despite concerns about cost-cutting measures and pipeline shifts, investors seem optimistic about BioMarin's future growth prospects, particularly with the Inozyme acquisition and the focus on rare disease treatments.
• The selling of shares by Hudson Bay Capital Management LP and Bellevue Group AG may have initially raised some eyebrows, but the increased holdings by other institutional investors like Dodge & Cox and Viking Global suggest confidence in BioMarin's long-term potential.
• Overall, the market's bullish response to BioMarin today could be attributed to a combination of new leadership, strategic acquisitions, and investor confidence in the company's ability to navigate through its current transformation phase successfully.

15.11.2025 - BMRN Stock was down 2.1%

• Hudson Bay Capital Management LP, Bellevue Group AG, and other institutional investors have decreased their stakes in BioMarin Pharmaceutical Inc., possibly indicating concerns about the company's immediate performance outlook.
• Despite falling short of quarterly earnings per share (EPS) estimates, BioMarin's positive guidance for FY2025 and ongoing restructuring efforts have generated optimism among investors. This is evidenced by increased holdings from Dodge & Cox, Viking Global, AQR, Geode, Norges Bank, and Boone Capital Management LLC.
• The market's response to the mixed signals of underperforming earnings but promising future projections implies that investors are considering the company's current obstacles against its growth potential and margin expansion through restructuring and late-stage trials.
• The fluctuation in BioMarin's stock price today results from a combination of short-term profit-taking by some investors and long-term confidence stemming from the company's strategic initiatives and advancements in its pipeline.

08.03.2025 - BMRN Stock was down 6.0%

• Today's downward trend in BMRN could be a result of investors taking profits following a period of positive developments and possible overvaluation.
• While the Phase 3 trial results for Palynziq in adolescent patients were encouraging, some investors may have anticipated even better outcomes, leading to selling pressure.
• Comparisons to CSL Limited in terms of valuation might have influenced investor attitudes, prompting some to reconsider their investment allocations in pursuit of perceived better opportunities.
• In conclusion, today's market behavior for BMRN appears to reflect a mix of profit-taking, unmet high expectations, and potential shifts in investor preferences within the sector.

15.00.2025 - BMRN Stock was down 5.3%

• Despite positive projections from financial analysts, BioMarin (BMRN) faced a notable decline in its stock value recently.
• The difference between the optimistic forecasts and the current market performance may be linked to general market sentiment, investor profit-taking, or unexpected negative developments impacting the company.
• Investor response to external factors like regulatory challenges, unsatisfactory clinical trials, or overall market instability likely contributed to the recent drop in BioMarin's stock value.

08.00.2025 - BMRN Stock was up 1.4%

• Investors have been analyzing BMRN alongside TECH to evaluate their investment potential.
• This comparison likely piqued investor interest in BMRN, resulting in heightened buying activity and the observed bullish trend.
• Trader sentiment regarding the relative value of BMRN compared to TECH may have prompted increased bullish positions on BMRN in today's trading session.

19.01.2026 - BMRN Stock was up 5.1%

• BioMarin's bullish movement today can be attributed to the positive sentiment surrounding the company, as highlighted by analysts and institutional investors increasing their stakes in the company.
• The upcoming conference call to discuss the fourth quarter and full-year 2025 financial results likely generated optimism among investors about the company's performance and future prospects.
• The continued interest from institutional investors, such as Aberdeen Group plc reducing its stake and New York Life Investment Management LLC making a new investment, indicates confidence in BioMarin's long-term growth potential.
• LSV Asset Management's significant increase in stake further reinforces the positive outlook on BioMarin, contributing to the bullish momentum in the stock price.

10.01.2026 - BMRN Stock was up 5.0%

• BMRN saw an upward trend today following positive analyst ratings and price target increases from various firms, including Piper Sandler, Barclays, and Canaccord Genuity.
• Factors such as the impending acquisition of Amicus Therapeutics and the upcoming data release for its experimental therapy INZ-701 have contributed to the positive outlook surrounding BMRN.
• Analysts view BMRN as undervalued with significant growth potential, anticipating revenue escalation and profit margin enhancement in the coming years.
• The company's strategic acquisitions and dedication to rare disease treatments have bolstered investor confidence, driving the bullish market performance.

12.01.2026 - BMRN Stock was up 1.1%

• Despite anticipated Q4 earnings decline, BioMarin Pharmaceutical (BMRN) saw an upward trend, reflecting investor confidence in its long-term prospects.
• Favorable ratings from analysts, adjustments in price targets, and excitement surrounding the impending acquisition of Amicus Therapeutics have contributed to the positive outlook for BMRN.
• The upcoming crucial data release for the experimental therapy INZ-701, designed for treating ENPP1 Deficiency, stands as a significant driver for BioMarin's presence in the rare disease market and likely heightened investor confidence.
• The generally optimistic sentiment towards BMRN, supported by promising forecasts, analyst support, and forthcoming catalysts, has outweighed worries about the projected earnings decline for the quarter.

04.03.2025 - BMRN Stock was down 10.4%

• Despite positive Phase 3 results for Palynziq in lowering blood Phe levels in adolescents, BioMarin's stock saw a bearish trend.
• The market may have reacted negatively due to profit-taking by investors after a recent run-up in the stock price following the positive results.
• Investors might be concerned about the timeline and potential challenges in getting label expansion approval from health authorities despite the promising data.
• The bearish movement could also be influenced by broader market conditions or sector-specific factors impacting biotechnology stocks.

20.01.2025 - BMRN Stock was up 6.3%

• BioMarin's Q4 adjusted EPS exceeding consensus expectations and providing strong sales guidance for 2025 has fueled investor confidence in the company's growth prospects.
• The positive earnings report and future outlook have likely attracted new investors and increased buying interest in the stock.
• The market's reaction indicates that investors are optimistic about BioMarin's ability to deliver on its financial targets and continue its success in developing treatments for rare diseases.

29.09.2025 - BMRN Stock was down 3.3%

• Analysts revised their forecasts for BioMarin Pharmaceutical following lower-than-expected earnings reported for the third quarter.
• Earnings for the quarter were 12 cents per share, missing the analyst consensus estimate of 37 cents per share.
• The unsatisfactory earnings likely shook investor confidence, leading to a bearish movement in the stock price.
• Investors may be worried about the company's future performance and its impact on its pipeline of therapies for rare genetic diseases.